Neuromuscular stimulator enters US trial:
This article was originally published in Clinica
NeuroControl has begun a multi-centre clinical trial in the US to assess its minimally invasive neuromuscular stimulator for treating shoulder pain in patients who have suffered a stroke. The StIM system is a miniaturised, multi-channel, programmable device designed to reduce shoulder pain and subluxation - the separation of the shoulder joint due to weak muscles. It delivers therapeutic stimulation through electrodes placed in the shoulder muscles. The Cleveland, Ohio based company CE-marked the StIM device for sale in Europe in January (see Clinica No 892, p 25).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.